信号通路介导乳腺癌内分泌治疗耐药的研究进展(4)
[16] Yardley D A,Noguchi S,Pritchard K I,et al.Everolimus plus exemestane in postmenopausal patients with HR+ breast cancer:BOLERO-2 final progression-free survival analysis[J].Adv Ther,2013,30(10):870-884.
[17] Crowder R J,Phommaly C,Tao Y,et al.PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer[J].Cancer Res,2009,69(9):3955-3962.
[18] Maira S M,Pecchi S,Huang A,et al.Identification and characteriza tion of NVP-BKM120, an orally available pan-class Ⅰ PI3-kinase inhibitor[J].Mol Cancer Ther,2012,11(2):317-328.
, http://www.100md.com
[19] Baselga J,Campone M,Osborne K,et al.PI3K inhibitor improves PFS in BELLE-2 trial[J].Cancer Discov,2016,6(2):115-116.
[20] Bendell J C,Rodon J,Burris H A,et al.Phase Ⅰ,Dose-Escalation Study of BKM120, an Oral Pan-Class Ⅰ PI3K Inhibitor,in Patients With Advanced Solid Tumors[J].Journal of Clinical Oncology,2012,30(3):282-290.
[21] Hong D S,Bowles D W,FalchookK G S,et al.A multicenter phase I trial of PX-866,an oral irreversible phosphatidylinositol 3-kinase inhibitor,in patients with advanced solid tumors[J].Clin Cancer Res,2012, 18(15):4173-4182.
, 百拇医药
[22] Bowles D W,Ma W W,Senzer N,et al.A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours[J].British Journal of Cancer,2013,109(5):1085-1092.
[23] Kaufman B,Mackey J R,Clemens M R,et al.Trastuzumab plus anas trozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive,hormone receptor-positive metastatic breast cancer:results from the randomized phase Ⅲ TAnDEM study[J].
, http://www.100md.com
J Clin Oncol,2009,27(33):5529-5537.
[24] Johnston S,Pippen J Jr,Pivot X,et al.Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer[J].J Clin Oncol,2009,27(33):5538-5546.
[25] Warenius H M,Kilburn J D,Essex J W,et al.Selective anticancer activity of a hexapeptide with sequence homology to a non-kinase domain of Cyclin Dependent Kinase 4[J].Molecular Cancer,2011,10(1):72.
, 百拇医药
[26] Steger G G,Gnant M,Bartsch R.Palbociclib for the treatment of postmenopausal breast cancer-an update[J].Expert Opin Pharmacother,2016, 17(2):255-263.
[27] Finn R S,Crown J P,Lang I,et al.The cyclin-dependent kinase 4/6 inhibitor palbociclib in combinatiaon with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive,HER-2 negative,advanced breast cancer(PALOMA-1/TRIO-18):a randomized phase 2 study[J].Lancet Oncol,2015,16:25-35., http://www.100md.com(范凤凤 郭宇)
[17] Crowder R J,Phommaly C,Tao Y,et al.PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer[J].Cancer Res,2009,69(9):3955-3962.
[18] Maira S M,Pecchi S,Huang A,et al.Identification and characteriza tion of NVP-BKM120, an orally available pan-class Ⅰ PI3-kinase inhibitor[J].Mol Cancer Ther,2012,11(2):317-328.
, http://www.100md.com
[19] Baselga J,Campone M,Osborne K,et al.PI3K inhibitor improves PFS in BELLE-2 trial[J].Cancer Discov,2016,6(2):115-116.
[20] Bendell J C,Rodon J,Burris H A,et al.Phase Ⅰ,Dose-Escalation Study of BKM120, an Oral Pan-Class Ⅰ PI3K Inhibitor,in Patients With Advanced Solid Tumors[J].Journal of Clinical Oncology,2012,30(3):282-290.
[21] Hong D S,Bowles D W,FalchookK G S,et al.A multicenter phase I trial of PX-866,an oral irreversible phosphatidylinositol 3-kinase inhibitor,in patients with advanced solid tumors[J].Clin Cancer Res,2012, 18(15):4173-4182.
, 百拇医药
[22] Bowles D W,Ma W W,Senzer N,et al.A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours[J].British Journal of Cancer,2013,109(5):1085-1092.
[23] Kaufman B,Mackey J R,Clemens M R,et al.Trastuzumab plus anas trozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive,hormone receptor-positive metastatic breast cancer:results from the randomized phase Ⅲ TAnDEM study[J].
, http://www.100md.com
J Clin Oncol,2009,27(33):5529-5537.
[24] Johnston S,Pippen J Jr,Pivot X,et al.Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer[J].J Clin Oncol,2009,27(33):5538-5546.
[25] Warenius H M,Kilburn J D,Essex J W,et al.Selective anticancer activity of a hexapeptide with sequence homology to a non-kinase domain of Cyclin Dependent Kinase 4[J].Molecular Cancer,2011,10(1):72.
, 百拇医药
[26] Steger G G,Gnant M,Bartsch R.Palbociclib for the treatment of postmenopausal breast cancer-an update[J].Expert Opin Pharmacother,2016, 17(2):255-263.
[27] Finn R S,Crown J P,Lang I,et al.The cyclin-dependent kinase 4/6 inhibitor palbociclib in combinatiaon with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive,HER-2 negative,advanced breast cancer(PALOMA-1/TRIO-18):a randomized phase 2 study[J].Lancet Oncol,2015,16:25-35., http://www.100md.com(范凤凤 郭宇)
参见:首页 > 医疗版 > 疾病专题 > 普通外科 > 乳腺癌